Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes

被引：14
|
作者：
Zweck, Elric [1 ]
Westenfeld, Ralf [1 ]
Szendroedi, Julia [2 ]
机构：
[1] Heinrich Heine Univ, Dusseldorf, Germany
[2] German Diabet Ctr, Dusseldorf, Germany
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2019年 / 381卷 / 21期
关键词：
GLP-1 RECEPTOR AGONISTS;
D O I：
10.1056/NEJMc1913157
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2075 / 2076
页数：2
相关论文
共 50 条
  • [31] Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial
    McGuire, Darren K.
    Busui, Rodica P.
    Deanfield, John
    Inzucchi, Silvio E.
    Mann, Johannes F. E.
    Marx, Nikolaus
    Mulvagh, Sharon L.
    Poulter, Neil
    Engelmann, Mads D. M.
    Hovingh, G. Kees
    Ripa, Maria Sejersten
    Gislum, Mette
    Brown-Frandsen, Kirstine
    Buse, John B.
    [J]. DIABETES OBESITY & METABOLISM, 2023, 25 (07): : 1932 - 1941
  • [32] Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
    Ugo Di Folco
    Noemi Vallecorsa
    Maria Rosaria Nardone
    Angelo Lauria Pantano
    Claudio Tubili
    [J]. Acta Diabetologica, 2022, 59 : 1287 - 1294
  • [33] Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes
    Chi, Cecilia
    Snaith, Jennifer
    Gunton, Jenny E.
    [J]. HEART LUNG AND CIRCULATION, 2017, 26 (11): : 1133 - 1141
  • [34] Semaglutide and Cardiovascular Outcomes
    Belkhouribchia, Jamal
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (08): : 767 - 767
  • [35] Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes
    Di Folco, Ugo
    Vallecorsa, Noemi
    Nardone, Maria Rosaria
    Pantano, Angelo Lauria
    Tubili, Claudio
    [J]. ACTA DIABETOLOGICA, 2022, 59 (10) : 1287 - 1294
  • [36] Cardiovascular outcomes in type 1 and type 2 diabetes
    Rosengren, Annika
    Dikaiou, Pigi
    [J]. DIABETOLOGIA, 2023, 66 (03) : 425 - 437
  • [37] A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
    Vanita R. Aroda
    Lawrence Blonde
    Richard E. Pratley
    [J]. Reviews in Endocrine and Metabolic Disorders, 2022, 23 : 979 - 994
  • [38] The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes
    Rasmussen, Mads Frederik
    [J]. DIABETOLOGY INTERNATIONAL, 2020, 11 (02) : 76 - 86
  • [39] Switching from subcutaneous to oral semaglutide in type 2 diabetes: A prospective study
    Martinez-Montoro, Jose Ignacio
    Picon-Cesar, Maria Jose
    Generoso-Pinar, Marta
    Fernandez-Valero, Andrea
    Lopez-Montalban, Angel
    Simon-Frapolli, Victor Jose
    Hernandez-Bayo, Juan
    Pinzon-Martin, Jose Luis
    Tinahones, Francisco J.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2024, 295 (01) : 113 - 115
  • [40] Cardiovascular outcomes in type 1 and type 2 diabetes
    Annika Rosengren
    Pigi Dikaiou
    [J]. Diabetologia, 2023, 66 : 425 - 437
12345